In vitro and in vivo interactions of selected nanoparticles with rodent serum proteins and their consequences in biokinetics by Kreyling, Wolfgang G. et al.
1699
In vitro and in vivo interactions of selected nanoparticles with
rodent serum proteins and their consequences in biokinetics
Wolfgang G. Kreyling*1,2, Stefanie Fertsch-Gapp1, Martin Schäffler1, Blair D. Johnston1,3,
Nadine Haberl1,4, Christian Pfeiffer5, Jörg Diendorf6, Carsten Schleh1,7,
Stephanie Hirn1,4, Manuela Semmler-Behnke1,8, Matthias Epple6 and Wolfgang J. Parak5
Review Open Access
Address:
1Institute of Lung Biology and Disease, Helmholtz Center Munich,
85764 Neuherberg/Munich, Germany, 2Institute of Epidemiology 2,
Helmholtz Center Munich, 85764 Neuherberg/Munich, Germany,
3Adolphe Merkle Institute, Université de Fribourg, 1723 Marly,
Switzerland, 4Walter Brendel Centre of Experimental Medicine,
Ludwig-Maximilians-Universität München, 81377 Munich, Germany,
5Fachbereich Physik, Philipps Universität Marburg, 35037 Marburg,
Germany, 6Inorganic Chemistry and Center of Nanointegration
Duisburg-Essen (CeNIDE), University of Duisburg-Essen, 45117
Essen, Germany, 7Berufsgenossenschaft Holz und Metall, 80809
München, Germany and 8Bavarian Health and Food Safety Authority,
85762 Oberschleissheim, Germany
Email:
Wolfgang G. Kreyling* - kreyling@helmholtz-muenchen.de
* Corresponding author
Keywords:
biokinetics; gold nanoparticles; protein corona; protein–nanoparticle
conjugate; serum protein binding; surface modification
Beilstein J. Nanotechnol. 2014, 5, 1699–1711.
doi:10.3762/bjnano.5.180
Received: 05 May 2014
Accepted: 16 September 2014
Published: 02 October 2014
This article is part of the Thematic Series "Biological responses to NPs".
Guest Editor: R. Zellner
© 2014 Kreyling et al; licensee Beilstein-Institut.
License and terms: see end of document.
Abstract
When particles incorporated within a mammalian organism come into contact with body fluids they will bind to soluble proteins or
those within cellular membranes forming what is called a protein corona. This binding process is very complex and highly dynamic
due to the plethora of proteins with different affinities and fractions in different body fluids and the large variation of compounds
and structures of the particle surface. Interestingly, in the case of nanoparticles (NP) this protein corona is well suited to provide a
guiding vehicle of translocation within body fluids and across membranes. This NP translocation may subsequently lead to accumu-
lation in various organs and tissues and their respective cell types that are not expected to accumulate such tiny foreign bodies.
Because of this unprecedented NP accumulation, potentially adverse biological responses in tissues and cells cannot be neglected a
priori but require thorough investigations. Therefore, we studied the interactions and protein binding kinetics of blood serum
proteins with a number of engineered NP as a function of their physicochemical properties. Here we show by in vitro incubation
tests that the binding capacity of different engineered NP (polystyrene, elemental carbon) for selected serum proteins depends
strongly on the NP size and the properties of engineered surface modifications. In the following attempt, we studied systematically
the effect of the size (5, 15, 80 nm) of gold spheres (AuNP), surface-modified with the same ionic ligand; as well as 5 nm AuNP
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with five different surface modifications on the binding to serum proteins by using proteomics analyses. We found that the binding
of numerous serum proteins depended strongly on the physicochemical properties of the AuNP. These in vitro results helped us
substantially in the interpretation of our numerous in vivo biokinetics studies performed in rodents using the same NP. These had
shown that not only the physicochemical properties determined the AuNP translocation from the organ of intake towards blood
circulation and subsequent accumulation in secondary organs and tissues but also the the transport across organ membranes
depended on the route of AuNP application. Our in vitro protein binding studies support the notion that the observed differences in
in vivo biokinetics are mediated by the NP protein corona and its dynamical change during AuNP translocation in fluids and across
membranes within the organism.
Introduction
Like any foreign material that enters into the organism, incorpo-
rated nanoparticles (NP) will bind with proteins of body fluids
and receptor proteins of cellular and organ membranes. Binding
of those proteins may cover the entire surface of the NP such
that in the following these proteins are interacting with their
biological vicinity and, hence, the subsequent fate of the NP is
determined by the types of proteins covering the NP. In other
words, the physicochemical properties of the NP play an essen-
tial role during protein binding but the biokinetics is largely
determined by the covering proteins and their dynamic
exchange in various biological fluids. This protein coating used
to be called opsonisation in the past but now the popular name
is “protein corona”. This protein corona is likely to be highly
dynamic and to change in different body fluids. Furthermore,
the most abundant proteins may bind first but get replaced by
higher affinity proteins [1-3].
Hence, already more than a decade ago it has been hypothe-
sized that soluble proteins in body fluids, such as blood or the
epithelial lining fluid of the lungs, may not only bind to incor-
porated nanoparticles but such conjugates will serve as ferry
boats navigated by interactions of those proteins with other
proteins including those in membranes. Hence, these
NP–protein conjugates behave like Trojan horses allowing
nanoparticles to float in body fluids, cross cellular and/or tissue
membranes, thereby reaching organs and tissues that were not
expected to accumulate and retain these NP. Proteins bind also
to submicrometer- or micrometer-sized particles, but the pecu-
liar behavior of translocating protein–NP conjugates within
body fluids and across organ membranes does not occur for
these larger particles since their masses are too large for
protein-mediated transport as we recently reviewed [4].
Although it was well known before that proteins bind to any
incorporated particle, we expected that the small size of the NP
similar to or slightly larger than the size of proteins will allow
for protein-mediated transport. The latter would be unique for
NP and would not be possible for larger particles in the size
range of micrometers. Here, we have focused on the biokinetics
of incorporated NP and did not consider any toxicological inter-
actions between the NP and proteins and their reaction partners,
which is currently a large scientific field studied by many
researchers.
Review
Binding of serum proteins to NP and forma-
tion of protein–NP complexes
Binding of selected proteins
First, we studied the parameters that determine the in vitro
binding kinetics of selected NP during a one-hour incubation in
simple phosphate-buffered saline (PBS) solutions in which a
given protein was dissolved at 0.4 mg/mL; details are given in
[5]. We chose nano-sized and submicrometer-sized carbon
black versus 50 nm monodisperse polystyrene NP with surface
modifications of either carboxyl groups (negative charge), or
amino groups (positive charge) or plain surface (neutral charge)
as measured by their zeta potential and agglomeration behavior
[5]. The proteins chosen were albumin, transferrin and apolipo-
protein A-1, which exist both in blood serum and in the lung
epithelial lining fluid. Protein concentrations before and after
NP incubation were determined by a depletion method using the
Bio-Rad protein assay. In all cases, a linear correlation of the
added amount of NP and the amount of bound proteins was
found and was described quantitatively by binding indices (BI,
Figure 1).
Hydrodynamic size distributions determined by dynamic light
scattering (DLS) and zeta potentials were determined for all
particles before and after incubation and showed varying
agglomeration during incubation; in addition the protein
coverage on the surface of each NP was estimated [5]. Table 1
summarizes the BI relative to the NP mass or NP surface area of
all three PS-NP and the two carbon black Printex 90 and Printex
G particles for all three proteins studied. The hydrophobic NP,
PS-Plain and Printex 90 show much higher NP-mass based
BImass for all three proteins than the hydrophilic PS-NP. Inter-
estingly, the mass-based BImass of Printex G with all three
proteins is also low because of the very small surface area of the
incubated sub-micrometer sized particles. When calculating the
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Table 1: Mass and surface area related to binding indices BI of the NP to the three different proteins, albumin, transferrin and apolipoprotein A-1.
Reproduced with permission from [5]. Copyright 2011 Informa Plc. Diameter refers to the geometrical diameter as observed with transmission elec-
tron microscopy (TEM), and does not take into account the hydration shell and adsorbed counter ions [6].







BSA transferrin Apo A-1 BSA transferrin Apo A-1 BSA transferrin Apo A-1
PS–Plain 50 120 49 56 43 407 466 359 66 ≈100 269/76
PS–COOH 50 120 2 13 13 17 104 116 <1 4 81/23
PS–NH2 50 120 5 5 <0 44 39 <0 <1 12 0
Printex G 50 30 9 12 11 313 398 360 ≈27 ≈62 ≈100
Printex 90 14 300 62 57 42 205 269 139 ≈8 ≈71 ≈100
Figure 1: Bovine serum albumin (BSA) depletion in the supernatant
after BSA separation from the 50 nm Polystyrene (PS) NP–protein
complexes (PS-Plain: neutral charge, PS-COOH: negative charge by
carboxyl groups, PS-NH2: positive charge by amino groups) depending
on the NP dose; the error bars show the standard deviation). Each line
represents the linear regression forced through the coordinate origin
with the slope representing the binding index (BI). BSA binds with a
much higher BI to hydrophobic, neutrally charged PS-Plain NP than
the two other hydrophilic PS-NP. Reproduced with permission from [5].
Copyright 2011 Informa Plc.
BI relative to the surface areas of the incubated particles then
the BIsurf values of all three hydrophobic particles are high but
the BIsurf values of the hydrophilic NP remain low. We also
estimated the surface coverage of the three proteins on the
particle surface and found that in case of the hydrophobic parti-
cles the coverage was rather complete whereas only a very tiny
surface percentage of the hydrophilic particles was covered
(Table 1).
Serum protein binding during in vitro incubation of
differently sized AuNP
In a second attempt we investigated the binding of the proteins
after an in vitro 24-hour incubation of monodisperse, nega-
tively charged gold spheres (AuNP) of 5, 15 and 80 nm core
diameter and surface modified with bis(p-sulfonatophen-
yl)phenylphosphine in diluted mouse serum in PBS (1:50 v/v)
by a two-step analysis: proteomic protein identification and
quantitative protein biochemistry [7]. The mass concentrations
of all AuNP varied from 6.7–200 µg/mL in steps of a factor of
three, corresponding to the accordingly calculated AuNP
surface area concentration (1–120 cm2/mL); thus, we obtained
surface area concentrations between 10–40 cm2/mL of all three
AuNP. Measurements by DLS before and after the AuNP incu-
bation showed an increase of the hydrodynamic size distribu-
tion and a less negative zeta potential as a result of the forma-
tion of the protein corona. Additional TEM analyses proved that
AuNP agglomeration was detectable but low, i.e., the changes
in the hydrodynamic size distributions were mainly caused by
the protein corona formation [7]. The proteins adsorbed to
AuNP were separated from non-adsorbed proteins by a three-
fold centrifugation–washing process (each ultracentrifugation at
165,000g up to one hour for 5 nm and 15 nm AuNP; 80 nm
AuNP were centrifuged and washed at 1000g for 20 min each
as their mass assured a rapid precipitation at this centrifugal
force). This was followed by protein detachment from the
AuNP of the first pellet (by using a lysis buffer based on lithium
dodecyl sulfate) and subsequently protein-mass-separation by
gel electrophoresis. Negative controls were performed on the
test tube used for the last washing step as well as on control
incubations without any AuNP. For protein identification a
MALDI-TOF MS proteomics analyzer was used. Furthermore,
proteins in gel bands were analyzed quantitatively by protein
densitometry. Only predominantly binding serum proteins could
be analyzed by this quantitative approach.
A typical electrophoresis gel visualized by Coomassie staining
is given in Figure 2, which shows a variety of proteins present
in the corona of the three differently sized AuNP. Proteins
cover the whole range of molecular weights from 20–220 kDa.
With increasing AuNP sizes, the gel shows decreasing band in-
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Figure 2: The size-selective separation of mouse serum proteins in the corona of the three differently sized AuNP are shown in the different gel lanes
(after incubation and washing). Molecular weights (kDa) derived from the marker proteins are given at the left and right side. Labeled proteins were
identified by MALDI–TOF MS. The number of bands and quantitative amount of adsorbed proteins differed between 5, 15 and 80 nm AuNP. Band in-
tensities of adsorbed proteins decreased with increasing AuNP sizes. Reproduced with permission from [7]. Copyright 2013 IOP Publishing.
tensities at the same mouse serum concentration and same
AuNP mass. The individual protein patterns show some similar-
ities but they are not identical (see below). Similarly prepared
gels of serum protein samples without AuNP proved to show no
proteins (negative control data not shown).
In a next step the role of the AuNP surface area available for
protein adsorption was studied since the same mass of smaller
AuNP have a larger surface area compared to large AuNP.
Different concentrations of AuNP suspensions were used repre-
senting different available AuNP surface areas (Figure 3).
Based on the total surface area of all AuNP expressed as the
sum of the individual surface areas of all monodisperse AuNP,
the three AuNP showed size-dependent protein-binding capaci-
ties for given total surface areas (Figure 3). For the same total
surface area 5 nm AuNP bound a much higher total protein
fraction compared to 15 nm AuNP and those bound a higher
protein fraction than the 80 nm AuNP.
In other words, fewer proteins bind to the 80 nm AuNP surface
area, which has the least surface curvature, compared to the
smaller AuNP. This result is in agreement with the notion that
the rather plain surface of the “big” 80 nm AuNP interacts only
Figure 3: After 24 h incubation the fraction of totally available proteins
binding to the AuNP is shown versus the calculated total surface area
of all AuNP (as a sum of the individual surface areas of the single
AuNP; mean ± SEM; n = 6). Reproduced with permission from [7].
Copyright 2013 IOP Publishing.
to a lesser extent with the three-dimensional structure of a
protein and the orientation of its binding sites compared to a
small AuNP (with a high curvature). These results indicate that
the higher the surface curvature of the AuNP, the higher the
protein binding capacity per surface area. Protein binding sites
Beilstein J. Nanotechnol. 2014, 5, 1699–1711.
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Table 2: Selection of murine serum proteins bound to the differently sized AuNP after 24 h of incubation. A total of nine SDS gels per AuNP were
investigated by using proteome analysis (MALDI–TOF MS). Only proteins are listed that were detected at least twice.
independent detections per
protein










serum albumin 9 8 3 69 osmotic pressure
hemoglobin 8 8 4 15 oxygen transport
fibrinogen beta 8 4 3 55 coagulation, immune response
Apo E 6 5 2 36 transport and cell uptake
Apo A1 9 7 — 30 metabolism
murinoglobulin 1 8 6 — 166 immune response
complement C3 7 8 — 186 immune response
alpha-2-macroglobulin 7 2 — 166 immune response
gelsolin 5 6 — 86 actin regulation (assembly)
fibrinogen gamma 5 4 — 50 coagulation, immune response
fibronectin 3 5 — 276 growth, migration and differentiation
Apo A4 6 — — 45 hepatic transcellular lipid transport
Apo A2 5 — — 11 transport
plasminogen 4 — — 93 peptidase
myosin-4 2 — — 224 muscle contraction
lg mu chain C region secreted form 2 — — 50 immune response
alpha-1-antitrypsin 2 — — 46 protease inhibitor
thrombospondin — 3 — 134 immune response
complement b — 2 — 86 immune response
plasma protease C1 inhibitor — 2 — 56 protease
antitrombin III — 4 — 52 protease inhibitor
actin — 3 — 42 cell mobility
vitronectin — 2 — 56 proteolysis regulation
protein spt 2 homologue — — 2 75 transcription
and their orientation and possible protein denaturation may
contribute to this result.
Of the 82 different proteins that were detected once on the three
AuNP we found 40 on the 5 nm AuNP, 35 on the 15 nm AuNP
and 19 on the 80 nm AuNP (more details are available in the
supplementary information of [7]). When considering only
those proteins which were detected twice or more in order to
improve the confidence of detection, 24 reproducibly detected
proteins were identified on the three differently sized AuNP: 17
different proteins on the 5 nm AuNP, 17 on the 15 nm AuNP
and 5 individual proteins on the 80 nm AuNP (Table 2).
Proteins which were detected at least twice on each of all three
differently sized AuNP were hemoglobin (oxygen transporter
protein in the circulation), serum albumin (most abundant blood
multi-functional protein), fibrinogen beta (modulation of blood
coagulation and opsonisation of foreign bodies [8]), and
apolipoprotein E (ApoE) (mediating protein for transcytosis
across biological membranes [9,10]). More detected proteins
were previously presented and discussed by Schäffler et al. [7].
In summary, multiple serum proteins were identified qualita-
tively by proteomic methodologies and quantitatively deter-
mined by protein biochemistry demonstrating that the compos-
ition of the protein corona in mouse serum depends on the size,
surface area and curvature of the AuNP [7].
Serum protein binding of 5 nm sized AuNP with
different surface modifications
In our next attempt we hypothesized that the configuration of
the protein corona (composition, size, geometric orientation)
depends on the surface ligands present on the AuNP. Therefore,
we studied the role of five different surface modifications on
monodisperse AuNP of 5 nm core diameter (i.e., the diameter as
determined by transmission electron microscopy). As surface
ligands we chose: citric acid (as supplied by the manufacturer),
bis(p-sulfonatophenyl)phenylphosphine, a thiol-PEG, and an
alkanethiol-ligand polymer shell with or without an additional-
ly bound amino-PEG. The characterization of NPs with similar
Beilstein J. Nanotechnol. 2014, 5, 1699–1711.
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Figure 4: Spherical monodisperse AuNP of 5 nm core diameter with five different ligands. The zeta potential in millivolts is given for each NP.
surface coatings has been reported in two previous papers [8,9].
Schematic sketches of the AuNP with their surface modifica-
tions are shown in Figure 4.
Besides the previous physicochemical characterizations [8], all
AuNP used in these experiments were thoroughly characterized
through TEM (size distribution), UV–vis spectroscopy
(absorbance), dynamic light scattering (DLS, hydrodynamic
diameter), differential centrifugal sedimentation (DCS) and
atomic force microscopy (AFM, morphology, height and
agglomeration). As a result, after incubation in either diluted
mouse serum in PBS (1:50 (v/v) or four-times concentrated
murine broncho-alveolar lavage (BAL) fluid based on Mg and
Ca ion free PBS (see below) the size distributions of the hydro-
dynamic diameters of all five AuNP were compared to the
corresponding AuNP suspensions in either PBS or distilled
water. As an example, the DCS measurements showed
that the spectral size shifts, from 5 nm AuNP in PBS or distilled
water to those after incubation in diluted mouse serum
or BAL fluid, did only increase by less than a factor of 2 of the
median diameter prior to incubation. This contrasts DLS and
AFM measurements, which yielded larger diameters of the
AuNP surface-modified with large molecules (bis(p-
sulfonatophenyl)phenylphosphine, thiol-PEG, polymer shell
with or without amino-PEG) even in PBS or distilled water. The
latter demonstrates that AFM and DLS include the surface
molecules into measurement of the size, while DCS does not
(Johnston et al. in preparation).
AuNP were incubated for 15 min or 24 h in either diluted
mouse serum or murine broncho-alveolar lavage fluid. After
incubation the suspension was centrifuged (75000g for
120 min) and washed three times to remove non-bound
proteins. Subsequently, one fraction was used for the determin-
ation of the hydrodynamic diameter distribution after incuba-
tion and from the other fraction proteins were separated from
the AuNP by a sodium dodecyl sulfate (SDS)-lysis buffer and
SDS-polyacrylyamide gel electrophoresis (PAGE) was carried
out. Thereafter, gel lanes were dissected in smaller units and
prepared for liquid chromatography mass spectroscopy/mass
spectroscopy (LC–MS/MS analysis). Figure 5 shows the protein
patterns of the most abundant proteins for all five AuNP in
mouse serum after 15 min of incubation. Figure 5 shows the
very good reproducibility of two independent LC–MS/MS
measurements for each of all five AuNP.
Biokinetics of AuNP after administration via
three routes of intake
The above mentioned in vitro studies were designed to provide
a better understanding about the role of proteins in blood and
other body fluids on the biokinetics of NP in the organism after
various routes of intake. The in vivo studies represent the main
Beilstein J. Nanotechnol. 2014, 5, 1699–1711.
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Figure 5: Protein percentages in cumulative stacks of the most abundant proteins bound to either of all five AuNP with different surface modifications
in mouse serum after 15 min incubation. The order of the proteins from the bottom to the top of the stack were chosen by the protein with the highest
binding percentage to the control AuNP (citrate stabilized) followed by proteins of successively lower binding percentages from bottom to top. Protein
abbreviations on the right column from top to bottom: Apoe: apolipoprotein E; Hc: hemolytic complement; Thbs1: thrombospondin 1; HPX: hemopexin;
Apoh: apolipoprotein H; Apob: apolipoprotein B; Serping1: serine (or cysteine) peptidase inhibitor; Apoa1: apolipoprotein A1; C4b: complement
component 4b; Hbb-b1: hemoglobin, beta adult major chain; Plg: plasminogen; Cfb: complement factor b; Kng1: kininogen 1; Cfh: complement
component factor h; Mug1: murinoglobulin 1; Pzp: pregnancy zone protein; Itih4: inter alpha-trypsin inhibitor, heavy chain 4; Gsn: gelsolin; Ahsg:
alpha-2-HS-glycoprotein; Fn1: fibronectin 1; Alb: albumin; C3: complement component 3.
focus of our research since the late 1990s. The knowledge about
the biokinetics of biopersistent NP is required when assessing
their toxicity in various organs and tissues and developing an
understanding of their potential risks. When particles are taken
up into the organism, they do not necessarily remain at their
initial sites of intake. Instead they can undergo numerous trans-
port processes within the various tissues of the organ of intake
and secondary organs and tissues.
Therefore, we developed and applied an in vivo assay on the
quantitative biokinetics of biopersistent NP in the organism of
experimental rodents. It aims for an overall quantitative esti-
mate of the total amount of the administered particles biodis-
tributed within and out of the body. The analysis of quantitative
biokinetics can be performed after the NP administration by any
route of intake, via the respiratory tract, the gastrointestinal
tract, the blood circulation or the skin. Basically, the total
amount of particles administered and retained in the entire body
is estimated at different time points after exposure and, in add-
ition, it includes the analysis of total excretion, Figure 6. There-
fore, the total of all NP incorporated are included in this
analysis: not only the NP distributions in organs and tissues of
interest, but also NP in the remaining carcass and those in the
excretion. As a result, the administered NP are 100% balanced
of and a complete and detailed quantitative analysis of their
biokinetics is obtained providing data on the fraction of NP per
organ or tissue but also NP mass- or NP surface- or number
concentrations per gram of organ or tissue (or those of other
metrics) .
We applied this in vivo assay and investigated systematically
the biokinetics of a suite of monodisperse, spherical gold NP
(AuNP) with Au core sizes of 1.4, 2.8, 5, 18, 80 and 200 nm in
healthy female adult Wistar Kyoto rats after administration via
three routes: intratracheal instillation into the lungs, intra-
venous injection into blood and intra-esophageal instillation
into the gastro-intestinal tract. The AuNP were synthesized and
surface-modified not only with small ionic ligands such as
sulfonated triphenylphosphine, amino groups, or carboxyl
groups, but also with polyethylene glycol (PEG) or other poly-
mers or polyelectrolytes and, finally, with tightly grafted plasma
proteins (albumin or apolipoprotein E). All AuNP had been
radioactively labeled with 198Au by neutron activation in a
nuclear research reactor. Most of these studies were published
in the following series of reports:
• biokinetics of 198AuNP of different small ionic ligand
surface modification: after intratracheal instillation or
intravenous injection of 1.4 nm and 18 nm 198AuNP;
Semmler-Behnke et al. [10]; after intravenous injection
Beilstein J. Nanotechnol. 2014, 5, 1699–1711.
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Figure 6: Schematics of the analysis of quantitative NP biokinetics. After particle administration at time t = 0 the whole urinary and fecal excretions
are collected separately. Animals are euthanized at times t1, t2, t3, etc., and organs and tissues of interest and the entire remaining carcass are
sampled (100% balanced sampling) and their weights or volumes are determined. Chemical analysis requires additional, separate steps of sample
preparation. When particles are radio-labeled, total organs and tissue samples including the entire remaining carcass will be analyzed directly by
using gamma spectrometry without any further preparation. Adapted from [4].
of 1.4, 2.8, 5, 18, 80 and 200 nm 198AuNP; Hirn et al.,
[11]; after intra-esophageal instillation of 1.4, 2.8, 5, 18,
80 and 200 nm 198AuNP; Schleh et al. [12]; after intra-
tracheal instillation of 1.4, 2.8, 5, 18, 80 and 200 nm
198AuNP Kreyling et al. [13],
• biokinetics of 198AuNP with PEG versus small ionic
ligand surface modification are compared after intratra-
cheal instillation or intravenous injection of 5 nm
198AuNP; Lipka et al. [14],
• biokinetics of protein–AuNP conjugates with albumin or
apolipoprotein E versus polyelectrolytes and a small
ionic ligand are compared after intravenous injection of
15 nm and 80 nm 198AuNP; Schäffler et al. [15],
• biokinetics of AuNP by double radio-labelling of Au
cores (198Au) and their polymer surface coating (111In)
with 4 nm core size; methodology was established: Ali et
al. [16]; biokinetics after intravenous injection (Kreyling
et al., manuscript submitted)
In this series of in vivo investigations we found similarities as
well as significant differences between the various AuNP and
their different physicochemical properties. Common to all
AuNP administered to the lungs by intratracheal instillation was
the predominant retention in the peripheral lungs [10]. In par-
ticular, more than 99% of AuNP with core diameters greater or
equal than 18 nm were retained in the lungs after 24 h [13].
However, the smaller the AuNP were, the more they translo-
cated into blood and accumulated in secondary organs such that
about 5% of the 1.4 nm AuNP were translocated from the lungs
into blood. This clearly indicates that the lungs are capable to
trap and retain NP at least at those low doses of 1–10 µg per
rodent lungs, even when the NP had been administered in a
bolus of suspended AuNP via intratracheal instillation. Interest-
ingly, translocation from lungs to blood increased proportion-
ally with the inverse of the Au core diameter (i.e., the specific
surface area (SSA) of these spherical AuNP) from 0.1% of
80 nm AuNP to 8% of 1.4 nm AuNP [13]. However, this SSA-
dependency did not apply for the 200 nm AuNP. Furthermore,
when considering how these translocated AuNP accumulated in
different organs and tissues the fractions were similar for all
AuNP and became independent of the AuNP size. Liver accu-
mulated about 10% of these translocated AuNP, which was
more than in other organs. However, the largest fraction of
about 50% was accumulated in the remaining carcass consisting
of the skeleton, soft tissue and skin. Estimating the skeletal
AuNP fraction about 15% of the translocated AuNP were accu-
mulated from blood to the bone marrow with its sensitive stem
cell population. For more details see [10,13].
After the intravenous injection of AuNP suspensions a reten-
tion is expected in the organs of the mononuclear phagocyte
system (MPS) with the largest fraction found in the liver.
Indeed, more than 98% of AuNP with core diameters ≥ 18 nm
were retained in the liver, particularly in Kupffer cells, and
about 1–2% were retained in the spleen [11]. However, the
smaller the AuNP were, the more they accumulated in other
organs such that only 50% of 1.4 nm AuNP were retained in the
liver. This decline was proportional to the inverse AuNP core
diameter. This is in contrast to the SSA-independent liver accu-
mulation for AuNP which had crossed from the lungs to blood
after intratracheal instillation, as mentioned above. Further-
more and in contrast to the SSA-independent accumulation for
AuNP which had crossed from the lungs to blood the accumula-
tion in the remaining carcass declined drastically from 25% for
1.4 nm AuNP to less than 0.2% for 80 nm and 200 nm AuNP.
Hence, when considering the inverse diameter (i.e., the SSA)
Beilstein J. Nanotechnol. 2014, 5, 1699–1711.
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the accumulation of the remainder increases sharply with SSA,
which is a clearly different behavior compared to intratracheal
instillation. For more details see [11].
After oral administration more than 99% of all AuNP were
excreted via feces. Yet, absorption and translocation across the
gut wall was clearly size dependent such that 0.4% of the nega-
tively charged 1.4 nm and 2.8 nm AuNP crossed the gut wall
while this fraction was smaller than 0.1% for all other AuNP.
Most of these absorbed AuNP accumulated in the remaining
carcass consisting of the skeleton, soft tissue and skin, which is
consistent with the findings after intratracheal instillation. For
more details see [12].
Twenty-four hours after administration via all three routes
significant amount AuNP still circulated in blood with the
actual fractions depending on the particle size. Highest frac-
tions were always found for the smallest AuNP. These findings
support the notion that the initially administered AuNP had
bound blood proteins including those which prevented recogni-
tion of the phagocytes of the organs of the MPS. In this context
we also studied the role of poly(ethyleneglycol) (PEG) surface
modifications on the biokinetics of AuNP of 5 nm Au core size
over 24 h [14]. Indeed we confirmed that applying long-chained
PEG (10 kDa) prolonged the circulation time of 95% of the
administered AuNP considerably after one hour, while the
circulation time was prolonged for only 2% of sulfonated tri-
phenylphosphine-modified AuNP of the same size. Yet, short-
chained PEG (750 Da) did not yield such a prolongation indi-
cating less stability of the PEG surface modification. Even for
the long-chained PEG only 15% of the initially administered
AuNP were still circulating after 24 h suggesting a gradual de-
gradation of the PEG shell.
Our in vitro studies clearly demonstrated the rapid binding of
serum proteins to AuNP. This is likely reflected in the in vivo
biokinetics results found after intravenous injection which led to
a predominant accumulation in the liver and Kupffer cell endo-
cytosis. Yet, the fact that even after 24 h a significant fraction of
AuNP still circulated in blood, points to a fraction of AuNP
bound to proteins, which had not been recognized by the phago-
cytic cells of the MPS. The fact, that AuNP showed a
completely different pattern of accumulation in the various
organs and tissues after translocation across either the air–blood
barrier of the lungs or the gut epithelium strongly suggests that
those AuNP had bound to different proteins compared to those
that bound to blood proteins after intravenous injection. It is
plausible to assume that this dynamic protein exchange
occurred during the translocation across membrane barriers by
either transcellular endo- and exocytosis, or by paracellular
transport mechanisms. While there are some in vitro studies
suggesting protein exchange on NP surfaces during membrane
crossing we are not aware of any in vivo studies having shown
such exchange [17-19]. Hence, our in vivo studies together with
our in vitro studies as well as other in vitro studies support the
notion that protein binding on NP surfaces does undergo
dynamic protein exchange when NP cross organ membranes.
In order to identify the role of individual proteins on the bioki-
netic fate of NP–protein conjugates we engineered such conju-
gates by using either albumin or apolipoprotein E grafted
through polyelectrolyte links onto the surface of 15 nm or
80 nm AuNP prior to intravenous injection into mice [15].
Indeed, we observed remarkable differences in the biokinetics
pattern during the first 48 h after administration. AuNP reten-
tion in the liver decreased drastically while AuNP retention in
lungs and spleen jumped up ten-fold for both protein–AuNP
conjugates of 15 nm AuNP core size when compared to citrate-
stabilized AuNP of the same size. In case of albumin–AuNP
conjugates, retention in the brain increased even 100-fold while
the retention of apolipoprotein-E–AuNP conjugates in the brain
was still 10-fold when compared to citrate-stabilized AuNP of
the same size. Similarly, retention of both protein–AuNP conju-
gates was also increased 10-fold in the remaining carcass
consisting of skeleton, soft tissues and skin. Interestingly, only
small increases were seen for the conjugates with 80 nm AuNP
core size indicating the relevance of the AuNP surface curva-
ture and the binding orientation of the conjugated proteins.
These results emphasize the determining role of distinct
proteins on the biokinetics of grafted AuNP conjugates.
However, these results also suggest that more research is
required to better understand the mechanisms of how these
proteins and others mediate the passage across organ
membranes.
Precision-cut lung slices after intratracheal instilla-
tion of PVP-coated silver NP
Several studies already described adverse effects of silver nano-
particles (AgNP) on the lungs [20-25]. However, information
about the effects of AgNP on diseased lungs is lacking. So, the
aim of the current study was to investigate the effects of AgNP
on lungs, which were subsequently incubated with lipopolysac-
charide (LPS) as a simple model for a bacterial infection. In
vivo pre-exposure of NP to the lungs leads to rapid clearance of
the NP out of the conducting airways and the dissolution/disso-
ciation of NP, but also to formation of the protein corona and
numerous cellular interactions between the NP and the lung
epithelium including functional and structural alterations of
proteins by Ag ions and also AgNP translocation into intersti-
tial spaces as described above. These interactions with proteins
and cells and the changes in the lung caused by both AgNP and
Ag ions are likely to modulate subsequent bacterial infections
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of the lungs in a way that can only be determined by an experi-
mental design like the one described below. For this purpose,
thin slices from rat lungs, so-called precision-cut lung slices
(PCLS), were employed. In PCLS the lung structure with all
proteins and important cell types is retained and the number of
test animals can be reduced by creating multiple PCLS from
one single lung. Thus, PCLS may represent a good ex vivo
intermediate between in vitro and in vivo test systems. In the
following we describe a pilot study anticipated to be followed
by in-depth proteomics and cellular analyses of lung tissue
exposed to AgNP and Ag ions as well as more realistic bacte-
rial post-exposures.
We used monodisperse, spherical, PVP-coated AgNP with a
size of 70 nm which had been carefully characterized [26,27].
The AgNP were dispersed in degassed distilled water and
the hydrodynamic diameter distribution was verified by
dynamic light scattering (DLS) measurements prior to intratra-
cheal instillation in groups of four healthy, adult, female
Wistar-Kyoto rats (8–10 weeks aged, body weight 180–200 g).
Doses of freshly prepared AgNP were 50 µg and 250 µg per rat
in 80 µL suspension. In addition, a dose of 250 µg AgNP in a
six-month old AgNP suspension and the corresponding AgNP-
free supernatant previously separated from AgNP by centrifuga-
tion (186000g, 30 min followed by ultrafiltration through a
15 kDa Amicon filter at 1500g for 15 min) that contained only
the released Ag+ ions was also tested. PBS served as a negative
control and 250 µg Ag+ ions from silver acetate served as a
positive control.
Twenty-four hours after instillation, rats were killed under deep
anaesthesia. The lungs were inflated at tidal volume with low-
melting agarose, excised and fixed in ice-cold saline. Cylinders
(8 mm diameter) of lung tissue were punched out and cut into
200 µm thick slices (precision-cut lung slices, PCLS). Four
PCLS were incubated in full medium in each well of 24-well
tissue culture plates. The plates were put into a 37 °C tissue
culture incubator, and the melting agarose as well as tissue
debris were removed by three washings of the medium within
the next hour. In order to simulate a bacterial infection in a first
attempt, LPS was added at increasing concentrations 1, 100,
500, 1000 and 5000 ng/mL into two wells for each concentra-
tion. Either after four or after twenty-four hours the viability of
the PCLS was tested by lactate dehydrogenase (LDH) analysis
for cell membrane damage and a WST-1 assay for mitochon-
drial activity in the cell culture supernatant as well as the release
of the pro-inflammatory cytokines tumor necrosis factor alpha
(TNF-α) and interleukin (IL-8) was analyzed.
After four hours, both viability tests demonstrated that the inte-
gral viability signals of the PCLS did not decrease with
increasing LPS concentrations up to 5 µg/mL. Yet, after the
second and third day, the viability decreased significantly (data
not shown). Similarly, the protein content of the PCLS did not
change for the same range of LPS concentrations during the
first 24 hours (data not shown). Further discussion including
cytokine release will be discussed below.
These ex vivo studies are complemented by in vivo studies,
after instillation of the same AgNP at the same doses, on toxico-
logical responses of rat lungs determined in broncho-alveolar
lavage fluids by using the same endpoints as in the ex vivo
studies described above [22]. Remarkably, the rather consistent
findings of increased pro-inflammatory response in an AgNP
dose-dependent manner as determined by several toxicological
endpoints in the in vivo studies were much less pronounced and
also inconsistently observed in the ex vivo PLCS studies. A
possible explanation of the inconsistent results is the fact that
the intratracheal instillation of the AgNP suspension led to a
rather inhomogeneous deposition in the lungs of the rats.
Furthermore, the PCLS represented a volume of lung tissue that
was insufficient and did not reflect the overall AgNP distribu-
tion in the lungs and their response. This leads to a large vari-
ability in the observed measurements. In contrast, the broncho-
alveolar lavages rinse most of the entire epithelial surface and,
hence, BAL fluid collects most of the pro-inflammatory
markers, which led to the rather consistent response depending
on the AgNP dose.
In the following, we present results shedding light on the
differences between the viability and the release of pro-inflam-
matory cytokines of PCLS exposed to either AgNP or
dissolved Ag or mixtures of both. The LDH release of PCLS
increased significantly when the rats were instilled with the
aqueous supernatants of AgNP centrifugation compared to
PCLS of untreated control rats (Figure 7). Consistently, LDH
was also increased in PCLS from rats treated with six-month
old, 250 µg AgNP. But this increase was not statistically
significant.
This indicates that dissolved/dissociated Ag species which had
been released from AgNP damaged the cell membrane of PCLS
more than the Ag+ ions from silver acetate. However, mito-
chondrial changes did not change in between any of the groups
of rats.
Interestingly, the inflammatory response determined by TNF-α
and IL-8 release increased significantly depending on the LPS
dose in PCLS of rats that were exposed to suspensions
containing 250 µg AgNP (Figure 8). It is quite striking that the
TNF-α release of PCLS exposed to 250 µg AgNP prepared six
months earlier was higher for each LPS concentration when
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Figure 7: Release of LDH in the supernatant after incubation of PCLS in tissue culture medium for 4 h. The animals had been treated 24 h before
either with 50 or 250 µg AgNP (freshly prepared or six months old) or silver acetate (250 µg Ag+) or AgNP-free supernatant after centrifugation of
AgNP. The percentage of total LDH-release from PCLS lysed with Triton X-100 is displayed. Data are represented as mean values ± standard errors
of the mean (SEM), with a sample size of n = 4.
Figure 8: Release of TNF-α in the supernatant after 4 h of incubation of PCLS (of untreated animals or animals treated with 250 µg AgNP (freshly
prepared or aged for six months), or silver acetate (250 µg Ag+) or AgNP-free supernatant) with increasing LPS-concentrations in the tissue culture
medium. The instilled volume was always 80 µL. Data are represented as mean ± SEM; n = 4–7; *,**,***: significantly different from PCLS exposed to
0 ng/mL LPS; *,**,***: significantly different from PCLS of untreated animals; p < 0.05 (*), p < 0.01 (**), p < 0.001 (***).
compared to 250 µg of freshly prepared AgNP. Furthermore,
for all LPS concentrations the TNF-α release of PCLS treated
with 250 µg Ag in silver acetate solution was rather similar to
those of the group treated with six-month old 250 µg AgNP. In
addition, the highest TNF-α release of PCLS for all LPS
concentrations was observed in PCLS that had been treated with
the AgNP-free supernatant (after AgNP removal by centrifuga-
tion and filtration). This result indicates that in a six-month old
AgNP suspension more dissolved/dissociated Ag species are
present in comparison to a freshly prepared AgNP suspension
[26]. In addition, these results are in line with the decreased
viability of PCLS in Figure 8, which were treated with 250 µg
AgNP in a six months old suspension or with AgNP free super-
natant. Obviously, the dissolved/dissociated Ag species released
from the AgNP in distilled water are more cytotoxic and more
damaging to cell membranes than the Ag+ ions in the silver
acetate solution.
A similar and, hence, consistent response pattern was
observed when analyzing the IL-8 cytokine response of the
PCLS of the various groups in Figure 9. Again, the highest
increase of IL-8 was observed when rats had been treated
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Figure 9: Release of IL-8 in the supernatant after 4 h of incubation of PCLS (from untreated animals or animals treated with 250 µg AgNP (freshly
prepared or aged for six months), or silver acetate (250 µg Ag+) or AgNP-free supernatant) with increasing LPS-concentrations in the tissue culture
medium. The instilled volume always was 80 µL. Data are represented as mean ± SEM; n = 4–7; *,**,***: significantly different from PCLS exposed to
0 ng/mL LPS; *,**,***: significantly different from PCLS of untreated animals; p < 0.05 (*), p < 0.01 (**), p < 0.001 (***).
with AgNP-free supernatant (after AgNP centrifugation) for all
LPS concentrations applied.
During the six months of aging, about half of the AgNP mass
becomes dissolved as was shown by Kittler and coworkers [26].
Hence, both the six-month old 250 µg AgNP suspension
and the AgNP-free supernatant contained similar concentra-
tions of Ag+ ions and/or dissociated Ag. Both, the AgNP
suspension and the supernatant were instilled directly into the
rat lungs. Upon contact with the epithelial lung lining fluid
containing 0.9% NaCl the instillate was spread out and diluted
such that Ag+ ions formed AgCl, which precipitated and
possibly formed nano-sized AgCl particles [27]. These AgCl
nanoparticles also underwent endocytosis in the lung epithe-
lium. Subsequently they were dissolved/digested intracellularly
probably faster than the engulfed AgNP that formed Ag+ ions or
other reactive Ag species, which apparently caused the
increased LDH release and the release of both cytokines [9,27].
Interestingly, instilled silver acetate showed a similar trend as
the suspension of the six-month old AgNP, albeit not such a
clearly increased release of LDH and cytokines. Note that silver
acetate is fully dissociated in water and the Ag+ ions will form
AgCl nanoparticles upon contact with the epithelial lung lining
fluid as do those in the AgNP suspension or in the AgNP-free
supernatant. This discrepancy suggests that the Ag dissociation
during aging of the AgNP suspension is more complex than just
forming Ag+ ions.
Conclusion
Upon contact with body fluids such as blood serum NP bind
soluble proteins according to their physicochemical surface
properties and the protein affinity and/or the abundance in
serum. The determining factors with regard to the NP were: NP
material, size, surface charge, surface curvature, surface ligand
modifications and their stability during incubation. Concerning
the proteins it was found that abundant proteins bind first but
become replaced over time by proteins of higher affinity to the
NP surface. When applying high sensitivity proteomics tech-
nologies such as LC–MS/MS, surprisingly many proteins were
detected within the different coronas of different NP. Besides
opsonizing proteins, other proteins were identified such as
transport and immuno-related proteins. This plethora of corona
proteins will mediate the NP navigation within body fluids and
across membranes and provides a plausible interpretation of the
very many sites of retention and accumulation of NP in various
organs and tissues of the organism.
Acknowledgements
The authors would like to thank Paula Mayer for her excellent
technical assistance. This work was supported by the German
Research Foundation (DGF, “Biological Responses to
Nanoscale Particles”, SPP 1313) and this review represents one
of the final reports of this priority program. The authors are
grateful to Dr. Torsten Hotopp from DFG for managing and
guiding the SPP 1313 funding initiative.
Beilstein J. Nanotechnol. 2014, 5, 1699–1711.
1711
References
1. Monopoli, M. P.; Walczyk, D.; Campbell, A.; Elia, G.; Lynch, I.;
Baldelli Bombelli, F.; Dawson, K. A. J. Am. Chem. Soc. 2011, 133,
2525–2534. doi:10.1021/ja107583h
2. Lundqvist, M.; Stigler, J.; Elia, G.; Lynch, I.; Cedervall, T.;
Dawson, K. A. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 14265–14270.
doi:10.1073/pnas.0805135105
3. Cedervall, T.; Lynch, I.; Lindman, S.; Berggård, T.; Thulin, E.;
Nilsson, H.; Dawson, K. A.; Linse, S. Proc. Natl. Acad. Sci. U. S. A.
2007, 104, 2050–2055. doi:10.1073/pnas.0608582104
4. Kreyling, W. G.; Semmler-Behnke, M.; Takenaka, S.; Möller, W.
Acc. Chem. Res. 2013, 46, 714–722. doi:10.1021/ar300043r
5. Fertsch-Gapp, S.; Semmler-Behnke, M.; Wenk, A.; Kreyling, W. G.
Inhalation Toxicol. 2011, 23, 468–475.
doi:10.3109/08958378.2011.583944
6. Rivera-Gil, P.; Jimenez De Aberasturi, D.; Wulf, V.; Pelaz, B.;
Del Pino, P.; Zhao, Y.; De La Fuente, J. M.; Ruiz De Larramendi, I.;
Rojo, T.; Liang, X. J.; Parak, W. J. Acc. Chem. Res. 2013, 46,
743–749. doi:10.1021/ar300039j
7. Schäffler, M.; Semmler-Behnke, M.; Sarioglu, H.; Takenaka, S.;
Wenk, A.; Schleh, C.; Hauck, S. M.; Johnston, B. D.; Kreyling, W. G.
Nanotechnology 2013, 24, 265103.
doi:10.1088/0957-4484/24/26/265103
8. Sperling, R. A.; Pellegrino, T.; Li, J. K.; Chang, W. H.; Parak, W. J.
Adv. Funct. Mater. 2006, 16, 943–948. doi:10.1002/adfm.200500589
9. Caballero-Díaz, E.; Pfeiffer, C.; Kastl, L.; Rivera-Gil, P.; Simonet, B.;
Valcárcel, M.; Jiménez-Lamana, J.; Laborda, F.; Parak, W. J.
Part. Part. Syst. Charact. 2013, 30, 1079–1085.
doi:10.1002/ppsc.201300215
10. Semmler-Behnke, M.; Kreyling, W. G.; Lipka, J.; Fertsch, S.; Wenk, A.;
Takenaka, S.; Schmid, G.; Brandau, W. Small 2008, 4, 2108–2111.
doi:10.1002/smll.200800922
11. Hirn, S.; Semmler-Behnke, M.; Schleh, C.; Wenk, A.; Lipka, J.;
Schäffler, M.; Takenaka, S.; Moller, W.; Schmid, G.; Simon, U.;
Kreyling, W. G. Eur. J. Pharm. Biopharm. 2011, 77, 407–416.
doi:10.1016/j.ejpb.2010.12.029
12. Schleh, C.; Semmler-Behnke, M.; Lipka, J.; Wenk, A.; Hirn, S.;
Schäffler, M.; Schmid, G.; Simon, U.; Kreyling, W. G. Nanotoxicology
2012, 6, 36–46. doi:10.3109/17435390.2011.552811
13. Kreyling, W. G.; Hirn, S.; Möller, W.; Schleh, C.; Wenk, A.; Celik, G.;
Lipka, J.; Schäffler, M.; Haberl, N.; Johnston, B. D.; Sperling, R.;
Schmid, G.; Simon, U.; Parak, W. J.; Semmler-Behnke, M. ACS Nano
2014, 8, 222–233. doi:10.1021/nn403256v
14. Lipka, J.; Semmler-Behnke, M.; Sperling, R. A.; Wenk, A.;
Takenaka, S.; Schleh, C.; Kissel, T.; Parak, W. J.; Kreyling, W. G.
Biomaterials 2010, 31, 6574–6581.
doi:10.1016/j.biomaterials.2010.05.009
15. Schäffler, M.; Sousa, F.; Wenk, A.; Sitia, L.; Hirn, S.; Schleh, C.;
Haberl, N.; Violatto, M.; Canovi, M.; Andreozzi, P.; Salmona, M.;
Bigini, P.; Kreyling, W. G.; Krol, S. Biomaterials 2014, 35, 3455–3466.
doi:10.1016/j.biomaterials.2013.12.100
16. Ali, Z.; Abbasi, A. Z.; Zhang, F.; Arosio, P.; Lascialfari, A.;
Casula, M. F.; Wenk, A.; Kreyling, W.; Plapper, R.; Seidel, M.;
Niessner, R.; Knöll, J.; Seubert, A.; Parak, W. J. Anal. Chem. 2011, 83,
2877–2882. doi:10.1021/ac103261y
17. Salvati, A.; Pitek, A. S.; Monopoli, M. P.; Prapainop, K.; Bombelli, F. B.;
Hristov, D. R.; Kelly, P. M.; Aberg, C.; Mahon, E.; Dawson, K. A.
Nat. Nanotechnol. 2013, 8, 137–143. doi:10.1038/nnano.2012.237
18. Ragnaill, M. N.; Brown, M.; Ye, D.; Bramini, M.; Callanan, S.; Lynch, I.;
Dawson, K. A. Eur. J. Pharm. Biopharm. 2011, 77, 360–367.
doi:10.1016/j.ejpb.2010.12.024
19. Brandenberger, C.; Rothen-Rutishauser, B.; Mühlfeld, C.; Schmid, O.;
Ferron, G. A.; Maier, K. L.; Gehr, P.; Lenz, A.-G.
Toxicol. Appl. Pharmacol. 2010, 242, 56–65.
doi:10.1016/j.taap.2009.09.014
20. Carlson, C.; Hussain, S. M.; Schrand, A. M.; Braydich-Stolle, L. K.;
Hess, K. L.; Jones, R. L.; Schlager, J. J. J. Phys. Chem. B 2008, 112,
13608–13619. doi:10.1021/jp712087m
21. AshaRani, P. V.; Mun, G. L. K.; Hande, M. P.; Valiyaveettil, S.
ACS Nano 2009, 3, 279–290. doi:10.1021/nn800596w
22. Haberl, N.; Hirn, S.; Wenk, A.; Diendorf, J.; Epple, M.; Johnston, B. D.;
Krombach, F.; Kreyling, W. G.; Schleh, C. Beilstein J. Nanotechnol.
2013, 4, 933–940. doi:10.3762/bjnano.4.105
23. Christensen, F. M.; Johnston, H. J.; Stone, V.; Aitken, R. J.; Hankin, S.;
Peters, S.; Aschberger, K. Nanotoxicology 2010, 4, 284–295.
doi:10.3109/17435391003690549
24. Gaiser, B. K.; Fernandes, T. F.; Jepson, M.; Lead, J. R.; Tyler, C. R.;
Stone, V. Environ. Health (London, U. K.) 2009, 8 (S2, Suppl. 1).
doi:10.1186/1476-069X-8-S1-S2
25. Johnston, H. J.; Hutchison, G.; Christensen, F. M.; Peters, S.;
Hankin, S.; Stone, V. Crit. Rev. Toxicol. 2010, 40, 328–346.
doi:10.3109/10408440903453074
26. Kittler, S.; Greulich, C.; Diendorf, J.; Köller, M.; Epple, M. Chem. Mater.
2010, 22, 4548–4554. doi:10.1021/cm100023p
27. Loza, K.; Diendorf, J.; Sengstock, C.; Ruiz-Gonzalez, L.;
Gonzalez-Calbet, J. M.; Vallet-Regi, M.; Köller, M.; Epple, M.
J. Mater. Chem. B 2014, 2, 1634–1643. doi:10.1039/C3TB21569E
License and Terms
This is an Open Access article under the terms of the
Creative Commons Attribution License
(http://creativecommons.org/licenses/by/2.0), which
permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
The license is subject to the Beilstein Journal of
Nanotechnology terms and conditions:
(http://www.beilstein-journals.org/bjnano)
The definitive version of this article is the electronic one
which can be found at:
doi:10.3762/bjnano.5.180
